BPM 31510, a clinical stage metabolic modulator, demonstrates therapeutic efficacy in glioblastoma models of temozolomide chemosensitive and resistance by targeting mitochondrial function Dadali, T., Kulkarni, S., Ng, R., Awate, P., Mogre, S., Diers, A. R., Jang, T., Merchant, M., Sun, J., Gesta, S., Thapa, K., Nagpal, S., Recht, L., Narain, N. R., Sarangarajan, R. AMER ASSOC CANCER RESEARCH. 2018

View details for DOI 10.1158/1538-7445.AM2018-873

View details for Web of Science ID 000468818902374